|
|
Article: Nabi Biopharmaceuticals Announces Results of StaphVAX(R) Confirmatory Phase III Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- November 1, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Study Failed to Show that StaphVAX Prevents S. aureus Infections in Kidney Disease Patients -
- Company to Increase Focus on Other Pipeline Products -
ROCKVILLE, Md., Nov. 1 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate Vaccine] failed to meet its primary endpoint in the company's confirmatory Phase III clinical trial.
The study, a randomized, double-blinded, placebo-controlled trial of 3,600 patients on hemodialysis, found no reduction in S. aureus types 5 and 8 infections in the StaphVAX group as compared to the placebo group. The company will immediately ...